Your browser doesn't support javascript.
The Pilot Study of Immunogenicity and Adverse Events of a COVID-19 Vaccine Regimen: Priming with Inactivated Whole SARS-CoV-2 Vaccine (CoronaVac) and Boosting with the Adenoviral Vector (ChAdOx1 nCoV-19) Vaccine.
Mahasirimongkol, Surakameth; Khunphon, Athiwat; Kwangsukstid, Oraya; Sapsutthipas, Sompong; Wichaidit, Mingkwan; Rojanawiwat, Archawin; Wichuckchinda, Nuanjun; Puangtubtim, Wiroj; Pimpapai, Warangluk; Soonthorncharttrawat, Sakulrat; Wanitchang, Asawin; Jongkaewwattana, Anan; Srisutthisamphan, Kanjana; Phainupong, Daraka; Thawong, Naphatcha; Piboonsiri, Pundharika; Sawaengdee, Waritta; Somsaard, Thitiporn; Ritthitham, Kanokphon; Chumpol, Supaporn; Pinyosukhee, Nadthanan; Wichajarn, Rattanawadee; Dhepakson, Panadda; Iamsirithaworn, Sopon; Phumiamorn, Supaporn.
  • Mahasirimongkol S; Medical Life Sciences Institute, Department of Medical Sciences, Ministry of Public Health, Nonthaburi 11000, Thailand.
  • Khunphon A; Medical Life Sciences Institute, Department of Medical Sciences, Ministry of Public Health, Nonthaburi 11000, Thailand.
  • Kwangsukstid O; Institute of Dermatology, Department of Medical Services, Ministry of Public Health, Bangkok 10400, Thailand.
  • Sapsutthipas S; Institute of Biological Products, Department of Medical Sciences, Ministry of Public Health, Nonthaburi 11000, Thailand.
  • Wichaidit M; Institute of Dermatology, Department of Medical Services, Ministry of Public Health, Bangkok 10400, Thailand.
  • Rojanawiwat A; National Institute of Health, Department of Medical Sciences, Ministry of Public Health, Nonthaburi 11000, Thailand.
  • Wichuckchinda N; Medical Life Sciences Institute, Department of Medical Sciences, Ministry of Public Health, Nonthaburi 11000, Thailand.
  • Puangtubtim W; Medical Life Sciences Institute, Department of Medical Sciences, Ministry of Public Health, Nonthaburi 11000, Thailand.
  • Pimpapai W; Medical Life Sciences Institute, Department of Medical Sciences, Ministry of Public Health, Nonthaburi 11000, Thailand.
  • Soonthorncharttrawat S; Medical Life Sciences Institute, Department of Medical Sciences, Ministry of Public Health, Nonthaburi 11000, Thailand.
  • Wanitchang A; Virology and Cell Technology Research Team, National Center for Genetic Engineering and Biotechnology (BIOTEC), National Science and Technology Development Agency (NSTDA), Pathum Thani 12120, Thailand.
  • Jongkaewwattana A; Virology and Cell Technology Research Team, National Center for Genetic Engineering and Biotechnology (BIOTEC), National Science and Technology Development Agency (NSTDA), Pathum Thani 12120, Thailand.
  • Srisutthisamphan K; Epidemiology Division, Department of Disease Control, Ministry of Public Health, Nonthaburi 11000, Thailand.
  • Phainupong D; Institute of Dermatology, Department of Medical Services, Ministry of Public Health, Bangkok 10400, Thailand.
  • Thawong N; Medical Life Sciences Institute, Department of Medical Sciences, Ministry of Public Health, Nonthaburi 11000, Thailand.
  • Piboonsiri P; Medical Life Sciences Institute, Department of Medical Sciences, Ministry of Public Health, Nonthaburi 11000, Thailand.
  • Sawaengdee W; Medical Life Sciences Institute, Department of Medical Sciences, Ministry of Public Health, Nonthaburi 11000, Thailand.
  • Somsaard T; Institute of Biological Products, Department of Medical Sciences, Ministry of Public Health, Nonthaburi 11000, Thailand.
  • Ritthitham K; Institute of Biological Products, Department of Medical Sciences, Ministry of Public Health, Nonthaburi 11000, Thailand.
  • Chumpol S; Institute of Biological Products, Department of Medical Sciences, Ministry of Public Health, Nonthaburi 11000, Thailand.
  • Pinyosukhee N; Medical Life Sciences Institute, Department of Medical Sciences, Ministry of Public Health, Nonthaburi 11000, Thailand.
  • Wichajarn R; Medical Life Sciences Institute, Department of Medical Sciences, Ministry of Public Health, Nonthaburi 11000, Thailand.
  • Dhepakson P; Medical Life Sciences Institute, Department of Medical Sciences, Ministry of Public Health, Nonthaburi 11000, Thailand.
  • Iamsirithaworn S; Epidemiology Division, Department of Disease Control, Ministry of Public Health, Nonthaburi 11000, Thailand.
  • Phumiamorn S; Institute of Biological Products, Department of Medical Sciences, Ministry of Public Health, Nonthaburi 11000, Thailand.
Vaccines (Basel) ; 10(4)2022 Mar 30.
Article in English | MEDLINE | ID: covidwho-1822473
ABSTRACT
In response to the SARS-CoV-2 Delta variant, which partially escaped the vaccine-induced immunity provided by two doses of vaccination with CoronaVac (Sinovac), the National Vaccine Committee recommended the heterologous CoronaVac-ChAdOx1 (Oxford-AstraZeneca), a prime-boost vaccine regimen. This pilot study aimed to describe the immunogenicity and adverse events of the heterologous CoronaVac-ChAdOx1 regimen, in comparison with homologous CoronaVac, and homologous ChAdOx1. Between May and August 2021, we recruited a total of 354 participants from four vaccination groups the CoronaVac-ChAdOx1 vaccinee (n = 155), the homologous CoronaVac vaccinee (n = 32), the homologous ChAdOx1 vaccinee (n = 47), and control group of COVID-19 patients (n = 120). Immunogenicity was evaluated by measuring the level of IgG antibodies against the receptor-binding domain (anti-SRBD) of the SARS-CoV-2 spike protein S1 subunit and the level of neutralizing antibodies (NAbs) against variants of concern (VOCs) using the plaque reduction neutralization test (PRNT) and pseudovirus neutralization test (pVNT). The safety profile was recorded by interviewing at the 1-month visit after vaccination. The anti-SRBD level after the second booster dose of the CoronaVac-ChAdOx1 group at 2 weeks was higher than 4 weeks. At 4 weeks after the second booster dose, the anti-SRBD level in the CoronaVac-ChAdOx1 group was significantly higher than either homologous CoronaVac, the homologous ChAdOx1 group, and Control group (p < 0.001). In the CoronaVac-ChAdOx1 group, the PRNT50 level against the wild-type (434.5 BAU/mL) was the highest; followed by Alpha variant (80.4), Delta variant (67.4), and Beta variant (19.8). The PVNT50 level was also found to be at its highest against the wild-type (432.1); followed by Delta variants (178.3), Alpha variants (163.9), and Beta variant (42.2), respectively. The AEs in the CoronaVac-ChAdOx1 group were well tolerated and generally unremarkable. The CoronaVac-ChAdOx1 heterologous regimen induced higher immunogenicity and a tolerable safety profile. In a situation when only CoronaVac-ChAdOx1 vaccines are available, they should be considered for use in responding to the Delta variant.
Keywords

Full text: Available Collection: International databases Database: MEDLINE Type of study: Experimental Studies / Randomized controlled trials Topics: Vaccines / Variants Language: English Year: 2022 Document Type: Article Affiliation country: Vaccines10040536

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Type of study: Experimental Studies / Randomized controlled trials Topics: Vaccines / Variants Language: English Year: 2022 Document Type: Article Affiliation country: Vaccines10040536